As the field of translational 'omics has progressed, refined classifiers at both genomic and
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …

Triple negative breast cancer (TNBC) is a highly heterogeneous disease with a poor
prognosis and a paucity of therapeutic options. In recent years, immunotherapy has …

Importance Agents targeting programmed death ligand 1 (PD-L1) have demonstrated
efficacy in triple-negative breast cancer (TNBC) when combined with chemotherapy and are …

Exercise has been proposed as a possible cancer treatment; however, there are an infinite
number of clinical oncology settings involving diverse cancer types and treatment protocols …

Simple Summary In this state-of-the-art breast biomarker review, we have tried to imagine
and illustrate future, emerging digital breast cancer ecosystems which allow for greater …

Molecular subtype of breast cancer has a great clinical significance and used as one of the
major criteria for therapeutic strategy. Recently, for anticancer therapy, the trend for …

Observational studies may play an important role in evaluating physical activity (PA) as a
cancer treatment; however, few studies have been designed, analyzed, or interpreted from a …

Breast cancer is the most common cancer among women in the world as well as in the
United States. Molecular and histological differentiation have helped clinicians optimize …

Simple Summary Triple Negative Breast Cancer (TNBC) comprises approximately 15–20%
of all breast cancer (BC) cases, is often diagnosed at an advanced stage, and is generally …

Introduction Triple-negative breast cancer (TNBC) continues to be a significant concern,
especially among minority populations, where treatment disparities are notably pronounced …